[211], who identified mutations in the EGFR pathway as well as alterations in PIK3CA, HER3, RET, BRAF, and NTRK1 as principal mechanisms of TKI resistance in NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.